智通财经网·2026-02-24 08:37Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Health Sciences Authority of Singapore for the marketing of its rivaroxaban tablets, marking a significant step in expanding its overseas market presence [1][2]. Group 1: Product Approval and Market Impact - The rivaroxaban tablets are indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. - The approval in Singapore is part of a broader strategy to enter Southeast Asian markets, with additional investments of approximately RMB 3.2482 million allocated for research and development related to this product [1]. - The presence of other approved manufacturers in Singapore, including Bayer, Teva, and Intega, indicates a competitive landscape, with Bayer being the primary seller [1]. Group 2: Market Data and Future Prospects - The total sales value of rivaroxaban tablets in Singapore for the year 2024 is projected to be USD 8 million across three specifications (10mg, 15mg, 20mg) [1]. - The approval of rivaroxaban tablets in Singapore is expected to have a positive impact on the company's efforts to expand its overseas market and gain valuable experience [2].